Evidence map›Paper›PMID 40835926›Full record

ArticleBMC medical genomics2025

The changes of immune function after neuroblastoma chemotherapy and the prediction of potential immune targets.

Yunfei Ma, Yan Su, Jing Huang, Wen Zhao, Cheng Huang, Jing Qin, Shengjie You, Yan Hu, Xin Ni

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC medical genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yunfei MaDepartment of Traditional Chinese Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, 56 Nanlishi Lu Xicheng District, Beijing, 100045, China.
Yan SuDepartment of Medical Oncology, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 100045, China.
Jing HuangPediatric Deparment of Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
Wen ZhaoDepartment of Medical Oncology, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 100045, China.
Cheng HuangDepartment of Medical Oncology, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 100045, China.
Jing QinDepartment of Medical Oncology, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 100045, China.
Shengjie YouDepartment of Traditional Chinese Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, 56 Nanlishi Lu Xicheng District, Beijing, 100045, China.
Yan Hu *Department of Traditional Chinese Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, 56 Nanlishi Lu Xicheng District, Beijing, 100045, China. huyan1302@sina.com.
Xin Ni *Department of National Center for Pediatric Cancer Surveillance, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, 56 Nanlishi Lu Xicheng District, Beijing, 100045, China. nixin@bch.com.cn.

Funding

Beijing "14th Five-Year Plan" key specialty of Chinese Medicine (leading class and demonstration class) BJZKLC005
6 · The paper itself

Abstract

backgroundHigh-dose chemotherapy for neuroblastoma is often intolerable for children, and its effectiveness is difficult to determine. Immunotherapy has become a popular research focus as a potential treatment. Therefore, identifying effective immune targets and drug synergistic chemotherapy against neuroblastoma is crucial.

methodsWe conducted proteomics exploratory analysis of urine from 12 neuroblastoma before and after chemotherapy. The immune-related differential proteins before and after chemotherapy were obtained through differential expression analysis and dynamic expression model analysis. The ESTIMATE and ssGSEA analyses used indirectly infer the characteristics of the immune microenvironment. Gene ontology and the Kyoto Encyclopedia of Genes and Genomes enrichment analysis were conducted to reveal the biological functions of the candidate genes.

resultsImmune analysis indicated that the immunosuppressive state in neuroblastoma patients caused by chemotherapy was closely related to CD8 T cells. Chemotherapy-associated differentially expressed proteins were significantly enriched in the mTOR signaling pathway. Neuroblastoma chemotherapy can significantly inhibit the expression of SEMA7A protein, and it is closely related to CD8T cell infiltration. Tetrachlorodibenzodioxin acting on SEMA7A was predicted using CTD databases.

conclusionsThis study combines proteomics and bioinformatics to predict and explore potential immune targets for synergistic chemotherapy against neuroblastoma, providing a new direction for clinical treatment that warrant further validation.

Indexed as

Antineoplastic AgentsNeuroblastomaComputational BiologyFemaleGene Expression Regulation, NeoplasticHumansMaleProteomicsSemaphorinsTumor MicroenvironmentAntineoplastic AgentsSemaphorinsBioinformaticsChemotherapyImmune functionNeuroblastomaProteomics

Identifiers

PMID40835926
PMCPMC12369135

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.